NYSE:RRMS (RRMS) (RRMS) Stock Price, News & Analysis → The best inflation-proof investment (From DTI) (Ad) Free RRMS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$27.16▼$27.1650-Day Range N/A52-Week Range$6.67▼$32.44VolumeN/AAverage Volume205,322 shsMarket CapitalizationN/AP/E Ratio63.16Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (RRMS) alerts: Email Address Ad InvestorPlace$21,000 in profits in six weeks? On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.Click here for details. About (RRMS) Stock (NYSE:RRMS)Rose Rock Midstream, L.P. owns, operates, develops and acquires diversified portfolio of midstream energy assets. The Company is engaged in providing midstream energy related services, such as crude oil gathering, transportation, storage, distribution and marketing in Colorado, Kansas, Minnesota, Montana, North Dakota, Ohio, Oklahoma, Pennsylvania, Texas and Wyoming. Its segments include Transportation, Facilities, and Supply and Logistics. Its Transportation segment operates crude oil pipelines and truck transportation businesses in the United States. Its Facilities segment operates crude oil storage and terminal businesses in the United States. Its Supply and Logistics segment operates a crude oil marketing and blending business in the United States. The Company operates in the Bakken Shale in North Dakota and Montana, the Denver-Julesburg Basin (DJ Basin) and the Niobrara Shale in the Rocky Mountain region, and the Granite Wash and Mississippi Lime Play in the Mid-Continent region.Read More Ad InvestorPlace$21,000 in profits in six weeks? On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.Click here for details. RRMS Stock News HeadlinesMay 1, 2024 | finance.yahoo.comImmunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journalApril 26, 2024 | finance.yahoo.comMultiple Sclerosis Market To Reach USD 39.9 Billion By 2032, Report By DataHorizzon ResearchMay 7, 2024 | InvestorPlace (Ad)$21,000 in profits in six weeks? On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.April 10, 2024 | finance.yahoo.comGranite Telecommunications Boosts EPIK Solution with Strategic Rapid Response Monitoring AllianceApril 4, 2024 | markets.businessinsider.comPolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximabMarch 27, 2024 | msn.comHow Everclear’s Art Alexakis combines rock and comedy to fight MSMarch 26, 2024 | msn.comWhen Does SPMS Begin?March 22, 2024 | msn.comSetPoint joins FDA’s TAP programme with MS deviceMay 7, 2024 | InvestorPlace (Ad)$21,000 in profits in six weeks? On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.March 15, 2024 | msn.comUnveiling Atlanta's Culinary Gems with Mike Jordan and Max HinesMarch 14, 2024 | msn.comSetPoint wins second FDA breakthrough device nod for neurostim deviceMarch 13, 2024 | sg.finance.yahoo.comExplainer-What is bitcoin's 'halving', and does it matter?March 13, 2024 | finance.yahoo.comSetPoint Medical Receives FDA Breakthrough Device Designation for its Neuroimmune Modulation Platform for the Treatment of Multiple SclerosisMarch 11, 2024 | finanznachrichten.dePolTREG S.A.: PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in PolandMarch 11, 2024 | markets.businessinsider.comPolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in PolandFebruary 29, 2024 | finance.yahoo.comEMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function BenefitsFebruary 28, 2024 | msn.comIndia gets breakthrough multiple sclerosis drug, but could be unaffordable to many at Rs 10+ lakh a yrFebruary 27, 2024 | msn.comMultiple sclerosis: SPMS vs. RRMS explainedFebruary 27, 2024 | finance.yahoo.comOM1 to Present Research on Multiple Sclerosis at ACTRIMS Forum 2024February 23, 2024 | msn.comChampioning Justice: Unveiling the Impact of Gideon's Promise at "Igniting Change" EventFebruary 21, 2024 | tmcnet.comPolTREG appoints Dan Shelly as Chief Business Development OfficerFebruary 12, 2024 | msn.comKadarius Toney trade regrade: Who won between Chiefs, Giants after WR's Super Bowl scratchFebruary 1, 2024 | msn.comBlack and Hispanic Women With Multiple Sclerosis Are More Likely to Have Complicated PregnanciesJanuary 31, 2024 | finanznachrichten.deSandoz Group: Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in GermanyJanuary 31, 2024 | msn.comSandoz launches biosimilar for multiple sclerosis in GermanyJanuary 31, 2024 | markets.businessinsider.comSandoz To Launch Tyruko Biosimilar For Multiple Sclerosis In Germany On Feb. 1January 31, 2024 | financialpost.comSandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in GermanySee More Headlines Receive RRMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (RRMS) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNYSE:RRMS CUSIPN/A CIK1527622 Webwww.semgroupcorp.com Phone+1-918-5248100FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio63.16 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report RRMS Stock Analysis - Frequently Asked Questions Is (RRMS) a good dividend stock? (RRMS) (NYSE:RRMS) pays an annual dividend of $2.64 per share and currently has a dividend yield of 0.00%. The dividend payout ratio is 613.95%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for RRMS. What other stocks do shareholders of (RRMS) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (RRMS) investors own include Aegean Marine Petroleum Network (ANW), Chipotle Mexican Grill (CMG), Endologix (ELGX), Express (EXPR), Hudson Technologies (HDSN), Pentair (PNR), Charles Schwab (SCHW), USG (USG), CARBO Ceramics (CRR) and Ritter Pharmaceuticals (RTTR). This page (NYSE:RRMS) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTIAI “wealth window” is closing June 25thParadigm PressThe 2024 crypto bull run has already started — don’t get left behindInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (RRMS) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
